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a b s t r a c t
Most currently-used antiretroviral drugs inhibit the reverse-transcriptase (RT) of HIV. The differences
between HIV-1 and HIV-2 RTs explain why some of the anti-HIV-1 drugs are not effective against HIV-2.
One major difference between the two HIV RTs is the low ribonuclease H (RNase H) activity of HIV-2 RT
relative to HIV-1 RT. Our previous studies showed that residue Gln294 in HIV-2 RT accounts for this
RNase H reduction (the comparable residue in HIV-1 RT is Pro294), as the Q294P mutant of HIV-2 RT has
10-fold higher RNase H. Here, we show that infectious HIV-2 cannot bear the replacement of the RT's
Gln294 by the HIV-1 RT Pro counterpart, as it results in substantially reduced HIV-2 replication and fast
reversions to the wild-type Gln294 virus. These ﬁndings prove the critical role of maintaining low RT-
associated RNase H activity in HIV-2. In contrast, HIV-1 can tolerate an about 10-fold higher RNase H.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The reverse transcriptases (RTs) of all retroviruses possess two
major catalytic functions, the DNA polymerase activity (that copies
both RNA and DNA templates into DNA) and the ribonuclease H
(RNase H) activity, which hydrolyzes the RNA in DNA–RNA hetero-
duplexes formed while copying the viral plus strand RNA (Cofﬁn et al.,
1997; Herschhorn and Hizi, 2010; Hizi and Herschhorn, 2008;
Menendez-Arias and Berkhout, 2008). The balanced combination of
these two enzymatic activities allows RTs to perform the complex
process of reverse transcription (RTN), in which the complete viral
single-stranded RNA genome is copied into double stranded DNA.
Due to the paramount signiﬁcance of the RTN process to the
replication cycle of retroviruses, RT is a chief target for drug treat-
ments against human immunodeﬁciency viruses (HIVs), the clinically
most important retroviruses that cause AIDS (Cofﬁn et al., 1997;
Herschhorn and Hizi, 2010; Menendez-Arias and Berkhout, 2008).
The molecules of both HIV-1 RT and HIV-2 RT are heterodimers,
consisting of two subunits (p66/p51 and p68/p54, for these two RTs,
respectively) (Cofﬁn et al., 1997; Herschhorn and Hizi, 2010; Hizi and
Herschhorn, 2008). The three dimensional structures of both HIV-1
and HIV-2 RTs have been resolved in a number of forms (Ding et al.,
1998; Huang et al., 1998; Jacobo-Molina et al., 1993; Kohlstaedt et al.,
1992; Ren et al., 2002). The larger subunit in these highly-related RTs
is composed of two domains, DNA polymerase and RNase H. The DNA
polymerase domain, which resembles a right hand (with ﬁngers,
palm and thumb subdomains), is joined to the RNase H domain by a
connection subdomain. The polymerase active site is located within
the palm subdomain of the larger subunit, whereas the RNase H
domain is located at the C-terminus of this subunit. The smaller RT
subunit is a limited proteolytic cleavage product of the larger subunit
(from which the whole C-terminal segment is removed); therefore, it
lacks the RNase H domain, while DNA polymerase domain of this
subunit has the same subdomains as the larger one (though the
relative folding in the heterodimers is different).
The speciﬁc DNA polymerase activities of puriﬁed recombinant
RTs of HIV-1 and HIV-2 are similar. Nevertheless, the RNase H
speciﬁc activity of HIV-1 RT was shown to be about 10-fold higher
than that of HIV-2 RT, generated from both the ROD and D194
strains of HIV-2 (Hizi et al., 1991; Shaharabany and Hizi, 1992). This
difference in the RNase H activity between the two HIV RTs is
quantitative rather than qualitative, since the pattern of RNA
cleavage by the two RTs is indistinguishable (Sevilya et al., 2003).
Selective chimeric recombinant RTs, derived from both HIV-1 and
HIV-2, have revealed that the protein's RNase H domain by itself
does not affect the level of RNase H activity. Instead, the RT's
polymerase domain in the smaller subunit has a major role in
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determining this RNase H level (Shaharabany and Hizi, 1992). The
protein segment responsible for this difference was traced to the
thumb subdomain in the small subunit; thus affecting the RNase H
activity presumably through interactions with the RNase H catalytic
domain of the larger subunit (Sevilya et al., 2001; Shaharabany and
Hizi, 1992). Only a single amino acid, residue 294, in the thumb of
the smaller RT subunit of the HIV RTs is responsible for the reported
difference in the RNase H activity (Sevilya et al., 2003). At this
position (located in the loop between helices aI and aJ in HIV-1 RT),
there is a proline in HIV-1 RT and a glutamine in HIV-2 RT. Thus, a
HIV-2 RT mutant, in which a proline substituted for the glutamine
in only the p54 subunit, exhibited in vitro an RNase H activity (and,
hence, a strand transfer activity) that is almost 10-fold higher than
that of the wild-type (WT) HIV-2 RT (and approximately as high as
WT HIV-1 RT). Steady-state kinetics of the RNase H activity
indicated substantial differences in the apparent Km values of the
RTs (with similar turnover numbers, kcat values). Thus, both WT
HIV-1 RT and the Q294P mutant of HIV-2 RT have an enhanced
afﬁnity towards the RNA-DNA substrate relative to WT HIV-2 RT,
with no signiﬁcant differences in the rates of the RNase H catalytic
process (Sevilya et al., 2003).
A parallel conversion of Pro294 in p51 of HIV-1 RT to a
glutamine caused a substantial decrease (by about 70%) in the
speciﬁc RNase H activity of the RT, suggesting that, as in HIV-2 RT,
residue 294 in HIV-1 RT is also critical for the RNase H function
(Sevilya et al., 2003). Interestingly, a systematic mutagenesis of the
Gln294 to ten different residues (in addition to Pro), representing
different chemical types of amino acid side chains, showed that all
modiﬁcations in the p54 subunit induced signiﬁcant increases of
the RNase H activity without affecting the polymerase activity
(Bochner et al., 2008). These overall in vitro results represent a
unique and rare case, in which every mutation introduced in a
speciﬁc residue of an active enzyme induces an increase rather than
a decrease in an enzyme's speciﬁc activity. Moreover, since the
balance between the RNase H and polymerase activity of all Gln294
HIV-2 RT mutants was increased, an expected parallel rise in the
strand transfer function was also observed (Sevilya et al., 2003).
The obvious question is whether a lower RNase H activity has
any beneﬁt to the biology of HIV-2, and why did WT HIV-2 RT retain
this lower activity imposed by Gln294. Consequently, we have
studied here the biology of a Q294P mutation in HIV-2 RT, in the
context of viral life cycle. This mutation was introduced in an HIV-2
infectious clone and the infectivity of the generated virions was
monitored in comparison to WT HIV-2. The results show that the
Q294P HIV-2 RT mutation leads to an impairment of viral infectiv-
ity, although the mutated virions were still infectious. Interestingly,
there was a rapid emergence of the Q294P revertants to the WT
HIV-2, with the original Gln294 residue. In all, the data show that
the excess of RNase H activity in HIV-2 leads to a reduction in virus
production, a condition that is strongly disfavored by the virus.
Results and discussion
The infectivity of susceptible cells by WT HIV-2, the Q294P mutant of
HIV-2 and by WT HIV-1
HEK293 cells were ﬁrst transfected with the plasmids that
harbor the infectious molecular clones of the full genomes of either
WT HIV-2 (pROD10) or the Q294P mutant (see Materials and
Methods). In parallel, the same procedure was performed with the
plasmid carrying WT HIV-1 (pSVC21). All three transfections
yielded similar virus amounts, as tested by reverse transcription
quantitative PCR (RT qPCR)—data not shown. The DNA polymerase
activities of the RT in lysates of the two versions of the transfection-
generated HIV-2 virions (WT and Q294P) were assayed in
comparison with puriﬁed recombinant WT HIV-1 RT that was
generated and studied by us earlier (Hizi et al., 1988; Hizi and
Shaharabany, 1992; Hizi et al., 1992; Hizi et al., 1991; Sevilya et al.,
2003; Sevilya et al., 2001). Since the speciﬁc DNA polymerase
activities of both WT HIV-1 and HIV-2 RTs as well as the Q294P
HIV-2 RT are similar (Sevilya et al., 2003), this positive RT control
suits the two HIV-2 RT versions. Indeed, the results shown in Fig. 1
indicate that the polymerase activity in both WT and Q294P HIV-2
strains are quite similar, suggesting that the synthesis, assembly
into virions, release from the transfected cells and proteolytic
processing of the mutant RT is not signiﬁcantly different from that
of the WT RT.
To test how many virions to use in all following infectivity
experiments, the RNA amounts from all virion batches, released by
the transfected cells, were quantitated by reverse transcribing the
viral RNAs that was followed by qPCR of the cDNA molecules
generated (see Materials and Methods). It should be emphasized that
in the comparative experiments described in this study, we have
used similar particle numbers of all tested strains, as determined by
RT qPCR. Virions were used to infect susceptible HeLa cells adapted
for the MAGI assay (Rosenbluh et al., 2007). 48 h post infection (PI),
the MAGI assay was conducted and the results show that all HIV
strains could infect the cells, albeit to variable extents (Fig. 2). The
quantitative results, presented in Fig. 2B, were calculated from three
independent experiments with the indicated standard deviations.
Thus, under the assay conditions, WT HIV-1 could infect the cells
better than WT HIV-2 (by about 2.2 fold).
The observed difference between WT HIV-1 and HIV-2 in the
MAGI assay is interesting by itself. In order to explain this result, one
alternative is to attribute this phenomenon to higher RNase H
activity of HIV-1 RT relative to that HIV-2 RT (Hizi et al., 1991;
Sevilya et al., 2003; Sevilya et al., 2001; Shaharabany and Hizi, 1992).
However, a parallel increase of the RNase H activity of HIV-2 RT to a
level similar to that of HIV-1 RT (as in the Q294P mutant) does not
convert HIV-2 to a more infectious virus, as HIV-1, but is rather
deleterious. Therefore, another explanation is that the difference
between WT HIV-1 and WT HIV-2 may result not from the RNase H
activities of the RTs but rather from differences in other viral genes/
proteins, such as the TAR structure that affects RNA translation by
being inhibitory for HIV-2 translation (Soto-Rifo et al., 2012). This
broader issue may require a further detailed investigation and it is
beyond the scope of the present speciﬁcally-studied issue.
The comparison between WT and the Q294P HIV-2 mutant was
adjusted to similar DNA polymerase activities of the mutant and
WT virions (supported by the results in Fig. 1). Therefore, in these
experiments, described below, the qPCR products were always
normalized according to equal U5 cDNA products (that solely rely
on the polymerase activity with no RNase H involvement)—see
below in Fig. 4. Both qualitative (Fig. 2A) and the quantitative
Fig. 1. RT assays on supernatants collected from HIV-2 transfected HEK293 cells.
Supernatants, collected 48 h post transfections, were assayed for RT activity using
dot blots, as described in Materials and Methods. 1- HIV-2 WT; 2- HIV-2 Q294P;
3- Mock infection; 4- A positive control of puriﬁed recombinant HIV-1 RT.
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results (Fig. 2B) imply that the Q294P mutant is signiﬁcantly
inferior to WT HIV-2 (by about 6.5-fold, as in Fig. 2B). To conﬁrm
this MAGI assay result, we have also performed a parallel assay to
assess the number of HIV-2 particles that were released 24 h PI,
employing RT qPCR. Here again, it is apparent that the infection by
WT HIV-2 generated about six-fold the amount of particles
produced by the Q294P mutant (Fig. 3). In all, it is apparent that
the Q294P mutation in HIV-2 leads to a considerable decline in the
infectivity relative to the WT virus.
The levels of RTN-produced cDNA products in cells infected by WT
HIV-2 and the Q294P mutant
The reduction in virus viability that resulted from the Q294P
mutation in HIV-2 RT, calls for additional mechanistic clariﬁca-
tions. This mutation increases the RT's RNase H activity by 10
fold while preserving the WT activity of the DNA polymerase
activity (Sevilya et al., 2003). By doing so, there is an increase in
the delicate balance between the RNase H and polymerase
activities. During the elaborate process of RTN, there are two
strand transfers (or template switching), in which the nascent DNA
strand switches from the copied template to a second template
that is further copied (Basu et al., 2008; Cofﬁn et al., 1997;
Herschhorn and Hizi, 2010). Previous in vitro studies, performed
by us on recombinant RTs, showed that in all HIV-2 RT mutants, in
which Gln294 was mutagenized to different residues (including to
a Pro), the increase in the speciﬁc RNase H activities (with no
effect on DNA polymerase) have led to a parallel increase in the
strand transfer function (Bochner et al., 2008; Sevilya et al., 2003).
Other studies carried out in infected cells have shown that a
change in RNase H/polymerase balance can substantially affect the
strand transfer processes associate with RTN. Thus, increasing the
RNase H/polymerase ratio (as in the case of mutations that
selectively impair polymerase activity) can cause higher strand
transfer rates (Nikolenko et al., 2004). In the present speciﬁc case
of HIV-2, the RNase H/DNA polymerase ratio was also increased,
but this time by increasing the RNase H rather than by reducing
the polymerase activity. Consequently, we have analyzed the viral
cDNA segments generated in infected cells 24 h PI with either the
WT or Q294P HIV-2. The qPCR technique was employed to
quantify the levels of the virus-synthesized cDNA (see Materials
and Methods). This was done by monitoring either the U5 DNA
segment that represents the (-) strong stop DNA, the U3 segment
(that is generated after the ﬁrst strand transfer) or the primer
binding site (PBS)-containing double-stranded DNA segment that
is synthesized after the second strand transfer (Basu et al., 2008;
Cofﬁn et al., 1997; Herschhorn and Hizi, 2010). After infection with
equal viral particles, the cellular DNAs were extracted and the viral
cDNA segments were assessed, using the proper primers (Table 1).
Speciﬁc primers detecting the original plasmids (Table 1) were
used also in order to assure that the results were not due to the
carryover of plasmid remnants (data not shown). The results of the
experiment described in Fig. 4, show that the levels of the qPCR-
produced U3 and PBS cDNA segments (normalized to equal U5
products) are similar for both the WT and mutant HIV-2. This
result strongly suggests that in the Q294P HIV-2 mutant, the
overall RTN-produced synthesis of cDNA was normal, namely, the
expected increase in RT-associated RNase H activity had no
apparent signiﬁcant effect.
HIV-1 WT
HIV-2 Q294PHIV-2 WT
Mock
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Q294P
Mock
Fig. 2. MAGI assay for the cell infectivity by WT HIV-2, the Q294P HIV-2 mutant and WT HIV-1. HeLa cells, expressing the CCR5 co-receptor (MAGI-CCR5), were infected with
equal virion amounts of WT HIV-1 (HXB2), WT HIV-2 (ROD strain) or the HIV-2 Q294P mutant. 48 h PI, a MAGI assay was performed (see Material and Methods) and the
positively-stained infected cells were counted under light microscopy. A. positively stained infected cells. In each experiment, at least 3 wells per virus were counted; scale
bar50 mm B. Quantiﬁcation of the three MAGI assays. Mock-infection with all reagents, except for virus. RU-relative units normalized to WT HIV-2 infectious particles, as
determined by adjusting to equal U5 RTN products (see text). Error bars represent standard deviation. n¼3.
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Fig. 3. Newly generated HIV-2 24 h PI. 24 h PI, the supernatant from HIV-2 WT or
Q294P infected cells were collected and the presence of the virus was quantiﬁed by
RT qPCR (see Material and Methods). RQ-relative quantiﬁcation (after adjusting to
equal U5 RTN products- see Fig. 2B). Error bars represent standard deviation. n¼3.
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The presence of integrated proviral cDNAs of WT HIV-2 and Q294P
mutant in the genome of infected cells
The results, shown so far, suggest that the Q294P HIV-2 mutant
is partially defective in replication, although the apparent RTN
products detected in the infected cells are similar to those
identiﬁed in WT-infected cells. This phenomenon calls for further
investigation to understand at which viral replication step the
mutant virus is partially inhibited. After the completion of the RTN
process, the viral genome enters the nucleus and can either
integrate into the genome or create, by an unknown mechanism,
nonproductive 2-LTR circle products (Cofﬁn et al., 1997; Julias
et al., 2001; Sloan and Wainberg, 2011). We could not detect such
2-LTR products in HIV-2 WT or the Q294P infected cells (data not
shown). Consequently, we have assayed the integrated proviral
products. To this aim, cells were infected with equal HIV-2 virion
numbers of the WT and the Q294P mutant; then, 24 h PI, the
cellular DNAs were harvested and tested for the presence of
integrated HIV-2 cDNA. First, we have PCR-ampliﬁed the DNA
segments that span the viral cDNA-cellular DNA boundaries, by
using a known repetitive Alu sequence primer and a HIV-2 LTR-
speciﬁc primer (Table 1). The reaction products were then ampli-
ﬁed again by “internal” qPCR reactions, carried out with HIV-2
speciﬁc primers (Table 1). The results, shown in Fig. 5, indicate that
infection with the HIV-2 mutant resulted in a 6.8-fold reduction in
the level of viral cDNA integration, relative to the WT virus. This
dissimilarity in the extent of viral cDNA integration is similar to
the observed differences between the WT and mutant virus, as
assessed from viral infectivity and production (in the experiments
described in Figs. 2 and 3). Therefore, the combined results suggest
that the lower virus production by the Q294P mutant can be
attributed to the lower integration of the RTN-produced viral
cDNA (although the syntheses of these cDNA products seem to
be quite normal).
In conclusion, there is an apparent disparity between the
seemingly-normal levels of RTN-synthesized cDNA, produced by
the Q294P mutant (relative to that of WT virus) (Fig. 4) and the
substantially lower levels of the integrated mutant proviral DNA
(Fig. 5). One possibility to explain this ﬁnding is to predict that a
considerable number of RTN-produced linear cDNA molecules of
the mutant were not integrated, due to aberrant terminal
sequences, as all retroviral integratable cDNAs must have (after
the IN-dependent removal of several extra terminal nucleotides)
the highly-conserved 30 terminal CA sequence (Cofﬁn et al., 1997).
Another plausible explanation is that, due to the apparent inter-
play between retroviral RTs and INs (Oz Gleenberg et al., 2005; Oz
et al., 2002; Tasara et al., 2001), the Q294P mutation in the RT
might have indirectly affected IN activities, thus leading to a
reduced integration. For example, we have already suggested that
the observed in vitro inhibition of IN by WT RT can inhibit the
deleterious process of auto-integration (Oz Gleenberg et al., 2005;
Oz et al., 2002). Therefore, if the Q294P HIV-2 RT mutation also
somehow attenuates this inhibition of IN by RT, a possible scenario
might be higher incidences of auto-integration (and, con-
sequently, a reduction in the correct integration of viral cDNA into
the host cell genomic DNA). Such an alternative calls for further
investigations.
Table 1
Oligos used in the current research a.
Primer name Purpose Sequence Reference
HIV-2 U3 Fw Amplifying HIV-2 U3 AGGAATTTGGGCACAAGTCA Current research
HIV-2 U3 Rev TTGCTTTCAGTCTCGCCTTC
HIV-2 PBS Fw Amplifying HIV-2 PBS TAGGACCCTTCTTGCTTTGG
HIV-2 PBS Rev GCCGTGTTCCAAGACTTCTC
HIV-2 U5 Fw Amplifying HIV-2 U5 and second round after ﬁrst Alu-PCR GCAGGTAGAGCCTGGGTGTTC (Basu et al, 2008)
HIV-2 U5 Rev CAGGCGGCGACTAGGAGAGAT
hGAPDH Fw Internal control AGCCACATCGCTGAGACA Universal ProbeLibrary #60 (Roche)
hGAPDH Rev GCCCAATACGACCAAATCC
Alu Amplifying integrated virus GCCTCCCAAACTGCTGGGATTACAG (Rosenbluh et al, 2007)
HIV-2 U5 out AAGGGTCCTAACAGACCAGGGTCT (Basu et al 2008)
Plasmid Fw Amplifying pROD10 backbone CAACCCGGTAAGACACGACT Current research
Plasmid Rev ACCTCGCTCTGCTAATCCTG
HIV-1 U5 Fw Amplifying HIV-1 U5 TCTGGCTAACTAGGGAACCCA (Mansky, 2000)
HIV-1 U5 Rev
a Out of this list of oligos, those used for qRT-PCR assays were checked for linearization performance in the range of 0.002pg–0.2ng.
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Fig. 4. qPCR of RTN products generated by HIV-2 24 h PI. Quantiﬁcation of RTN
products by qPCR of ﬁrst RTN product (U5), product after ﬁrst strand transfer (U3),
and product of the second strand transfer (PBS) (see Materials and Methods). RQ-
relative quantiﬁcation (after normalizing to equal U5 RTN products). Error bars
represent standard deviation. n¼3.
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Fig. 5. HIV-2 integration 24 h PI. Integration quantiﬁcation of HIV-2 in MAGI-CCR5
cells by Alu-PCR, followed by nested qPCR (see Materials and Methods). RQ-relative
quantiﬁcation. Error bars represent standard deviation. n¼3.
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The stability of the Q294P mutation in HIV-2 virions during viral
replication
It is apparent from the results presented so far, that the HIV-2
virions with the Q294P RT mutation lose some of their ﬁtness with
regard to replication. Therefore, it was interesting to test whether
this mutation is retained during the viral replication cycles, or is
there a selective pressure to mutate it back to the WT virus. To this
aim, we have infected cells with equal amounts of WT HIV-2 or the
Q294P mutant virus. After washing the unbound virions, the newly-
synthesized released virions were collected daily, from 1–7 days PI.
The cDNA was synthesized from the extracted viral RNA, and the
DNA sequences, encompassing the Q294P RT-encoding region, were
determined (see Materials and Methods). Representative results are
shown in Fig. 6. It is apparent that, 24 h PI, the mutant virus still
contains the original CCC codon, encoding its original Pro. However,
only 2 days PI, the codon was already mostly CAG (Gln), while the
WT virus retained its original Gln-encoding sequence. Once the
Q294P mutant reverted to the WT Gln294, it retained this Gln for as
far as we have continued harvesting and analyzing the produced
viruses (up to 30 days—data not shown). This experiment was
repeated independently three times, yielding identical results.
Moreover, we have checked in all experiments for the presence of
minute residual amounts of the original HIV-2 plasmid, to eliminate
its possible interference in the results (using qPCR with plasmid-
speciﬁc primers- Table 1). The conclusionwas that the levels of such
contaminations were always negligible and, hence, did not affect
the results (data not shown).
To summarize the results shown so far, it is clear that, in the
speciﬁc case of HIV-2 (and unlike HIV-1), a Pro at the RT's position
294 is highly disfavored. This is evident from both the signiﬁcantly
reduced replication rates of the mutant virus (that probably results
from impaired integration of viral cDNA) and from a strong
selective pressure to revert to the WT Gln. The question is why
the Q294P mutation is not accepted, leading to such a fast
reversion process. It should be emphasized that, to perform this
reversion, the virus should undergo two successive mutations in
the sequence encoding RT residue 294 (from the CCC, used in this
study, to a CAG). Interestingly, there are two Gln-speciﬁc codons
(CAG and CAA), so the conversion from the Pro-speciﬁc codon
(CCC) to a Gln codon could go either way. Yet, the majority of the
revertants have the WT CAG codon and not CAA.
Mutation rate of WT and Q294P HIV-2 strains
The observed fast reversion form the Q294P-mutated RT to the
WT enzyme could be explained by a higher mutation rates imposed
during the RTN process by the Q294P HIV-2 RT, relative to the WT
RT. In order to ﬁnd if there are differences between the mutation
rates in the Q294P and WT HIV-2 viruses, we analyzed the ﬁnal
product of productive RTN, the integrated cDNA. We used two-step
Alu-LTR PCR procedure to amplify only the sequences of the
integrated proviruses obtained 24 h PI and obtained single cDNA
fragments-containing plasmid clones (see Materials and Methods).
After sequencing the virus-produced cDNA fragments (that are
parts of the U5 region), we have compared the mutation rates in
the WT and the Q294P-produced proviral DNAs. For this compar-
ison, the appropriate segments of the integrated viral genomes of
12 WT HIV-2 clones (altogether, 5453 nts) and 14 clones of the
Q294P mutant (a total of 6233 nts) were analyzed. Under these
speciﬁc experimental conditions, the sequenced DNAs showed no
signiﬁcant differences between the frequencies of mutations gen-
erated by the WT and the mutant viruses (33.0104 and
33.7104 mutations per nucleotide, for the WT and Q294P
strains, respectively). These comparative results suggest that the
rapid reversion of the Q294P to the WT Gln294 RT does not seem to
result from a general impairment of the ﬁdelity of DNA synthesized
by Q294P HIV-2 RT. However, this ﬁnding still does not exclude the
possibly that the mutated regions of the RT-encoding gene are
preferentially mutated by the Q294P mutant, by being “hot spots”
for its RT-driven mutagenesis. It should be also mentioned that the
hereby-observed error rate for HIV-2 virus is substantially higher
1 day  
PI
Mutant
CCC
2 days 
PI 
WT
CAG
2 days 
PI
Mutant
CAG
Fig. 6. Reversion of the HIV-2 Q294P mutant to WT virus. Viruses (HIV-2 WT and Q294P mutant) collected one and two days PI. The viruses were treated by RT PCR; the
mutation area was ampliﬁed and sequenced (see Materials and Methods). One Representing experiment chromatograms out of three is shown. The rectangle deﬁnes residue
294-encoding codon in HIV-2 RT.
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than the comparable rates detected in experiments conducted with
cell culture-grown HIV-1, 2.2105 (Abram et al., 2014) or
3.4105 (Mansky, 2000). In these experiments, the error rates
were tested by an in vivo assay for detecting forward mutations in
HIV-1, using the lacZ α peptide gene as a reporter for mutations.
Interestingly, these error rates are much lower than those detected
in vitro, using puriﬁed WT HIV-1 RT- for example, 9.7103 (Curr
et al., 2006), or even 20103 (Alvarez et al., 2009). As far as we
know, no parallel thorough in vivo studies regarding spontaneous
mutations in HIV-2 were published so far. To exclude the possibility
that the obtained error rates in HIV-2 were biased by the experi-
mental system used, we have also calculated the error frequency
generated by WT HIV-1, grown and analyzed exactly as described
here for the WT and Q294P HIV-2 strains. The results indicate that
the error rate in HIV-1 was less than one mutation per 104
nucleotide (10,755 nts from 20 clones were sequenced and not
even a single mutation was detected). Altogether, the results shown
here may imply that HIV-2 is much more error prone than HIV-1,
although our previous studies, which compared the in vitro ﬁdelity
of WT RTs of HIV-1 and HIV-2, implied similar error proneness
(Bakhanashvili and Hizi, 1992a, b). In all, it might be possible that
there is something about HIV-2 (both the WT and Q294P mutant)
that is distinctive to this speciﬁc virus and is incompatible with the
common notion regarding error rates in retroviruses. Therefore, this
perplexing issue regarding the mutation rates in HIV-2 calls for
further thorough future studies.
Analyses of RT residue 294 in various natural isolates of HIV-2, SIV
and HIV-1
In light of the results presented here, we have examined in the
available published sequences (spanning those encoding RT resi-
due 294) as many as possible virus variants—to test whether and
how residue 294 is conserved. The analyses, calculated from
http://www.hiv.lanl.gov, indicate that, out of all 878 HIV-2 RT
sequences tested, a striking majority of 856 (97.5%) have a Gln294,
proving that this residue is highly conserved (Table 2). Out of the
22 other none-Gln294 HIV-2 clones, the majority of 15 are Glu294
and very few are Leu, His or Lys. Strikingly, none of them is a Pro.
We have already found in vitro that every mutation introduced at
position 294 leads to an increase in RNase H, including Q294A,
Q294H and Q294R (Bochner et al., 2008). Thus, it is possible that in
these 22 cases, where Gln294 was modiﬁed, there are other
unknown minor mutations in other RT regions, which may
compensate for the potentially higher RT-associated RNase H
activity of the mutants. Unfortunately, only few of these 22
sequences contain the full RT-encoding sequences, and even in
those, we were unable to detect any patterns that could suggest
which residues can compensate for the Gln294 mutation (data not
shown). A further support to this high conservation level of HIV-2
RT Gln294 emerges from the ﬁnding that all 56 analyzed
sequences of SIVsmm (that is the SIV strain mostly related to HIV-
2) harbor also Gln294. Taken together, Gln294 is required for the
optimal viability of HIV-2 and SIVsmm viruses.
As for HIV-1 RT, an inspection of 2233 isolates of HIV-1 pol
genes reveals that Pro294 is conserved in an overwhelming
majority of 98% (Table 2), implying the importance of Pro at this
position. Interestingly, in three of HIV-1 RT variants (0.13%) there is
a Gln294. We have already found that there is substantial reduc-
tion in the RNase H activity of the recombinantly expressed P294Q
mutant of HIV-1 RT (Sevilya et al., 2003). Therefore, it is possible
that a combination of other RT mutations, in these three HIV-1
isolates, can compensated for the potentially-low RNase H activity
of these P294Q mutants of HIV-1 RT (by increasing the enzyme's
activity). However, it might be as well, that these three P294Q
isolates did not acquire compensatory mutations and, thus, have a
reduced replicating capability.
In conclusion, we have presented evidence that the Q294P RT
mutation in HIV-2 RT is not lethal to the virus, and, despite being
deleterious, it can be partially tolerated (at least for a short replica-
tion time). Not only that, but the levels of cellular RTN products,
generated by infecting the cells with the mutant Q294P virions are
roughly similar to those observed with WT virus. Beyond this step of
retroviral replication, the integration of the de novo-synthesized viral
cDNA is already impaired, as is the production of new virions.
However, the most striking result is that the higher level of RNase
H activity of HIV-2 RT, to a level similar to that exhibited by HIV-1 RT,
is disadvantageous in the context of even few replication cycles of
HIV-2, as evident from the very rapid emergence of revertants to the
WT Gln294 (Fig. 6). This implies that HIV-2 strongly prefers the
lower RNase H activity of its RT. Interestingly, in HIV-1, a serial
reduction in the RT's DNA polymerase or RNase H activity has shown
that there is generally an excess of both polymerase and RNase H
activities in the infectious virions. The reduction in RNase H activity
had a lesser effect on viral replication than the effect of an impaired
polymerase activity (Julias et al., 2001). The presently-described case
of HIV-2, where a large increase in RNase H, rather than the common
case of a decrease, was caused by single mutation, makes it an
exceptionally-unique occurrence. In this speciﬁc case, a higher
activity is deﬁnitely not an advantageous one.
Materials and methods
Cell culture techniques
Monolayer adherent HeLa MAGI-CCR5 (Deng et al., 1996) and
HEK293 cells were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM). Cells were incubated at 37 1C in 5% CO2 atmosphere. All
media were supplemented with 10% (v/v) fetal calf serum, 0.3 g/
liter L-glutamine, 100 units/ml penicillin, and 100 units/ml strep-
tomycin (Biological Industries, Israel). Cells older than two month
were not taken for HIV infection assays.
Virus preparation
The infectious plasmids for producing WT HIV-1 was pSVC21 (a
generous gift from M. Kotler), and for WT HIV-2 was pROD10 (a
generous gift from K. Strebel). The mutant HIV-2 Q294P virus was
generated by us from the pROD10 plasmid. All plasmids were used
to transfect HEK293 cells, employing the TurboFect Cell Transfec-
tion Reagent (Fermentas), according to the manufacturer's instruc-
tions. Preparation of the viruses, and the subsequent infection
assays were performed in a class 2þ bio-safety level laboratory.
24 h post transfection, the medium was removed and cells were
washed twice with 1XPBS and supplemented with fresh medium.
To check virus titters, the transfected cells were cultured in DMEM
Table 2
Conservation of residue 294 in the RTs in natural isolates of HIV-1, HIV-2 and SIVa.
Virus Residue in position 294 % Number of sequences
HIV-2 Q 97 856/878
E 1.7 15/878
L 0.46 4/878
H 0.23 2/878
K 0.11 1/878
SIV Q 100 56/56
HIV-1 P 98 2189/2233
a Sequences were obtained from NCBI (www.ncbi.nlm.nih.gov), all aligned and
analyzed with the BioEdit program.
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complete medium for 24, 48, or 72 h. At each time point, the
medium was removed and ﬁltered through a 0.45 mM Millipore
ﬁlter. The virus-containing medium was aliquoted and stored at
80 1C. The number of virus particles in the mediumwas analyzed
afterwards, by reverse transcription (using Transcriptor Universal
cDNA Master Kit from Fermentas), followed by quantitative PCR (RT
qPCR), (using virus-speciﬁc primers). The following qPCR is
described below.
The multinucleate activation of galactosidase indicator (MAGI)
infection assay
The protocol was previously described (Rosenbluh et al., 2007).
Brieﬂy, 1.1104 MAGI-CCR5 cells were plated in a 96 well plate. 24 h
later, the cells were infected with a multiplicity of infection (MOI) of
0.01 of WT HIV-1, determined by the method described earlier (Janas
and Wu, 2009). After determining the amounts of HIV-1 RNA
molecules by RT qPCR, equal particles number of WT HIV-2 and
Q294P HIV-2 were also all determined by this method—to ensure
equal amounts of virions in all infectivity experiments. Before
infection, the medium was removed from each well and viral
dilutions, in a ﬁnal 50 ml volume (of complete DMEM in the presence
of 20 mg/ml DEAE-Dextran), were added to each well. Then, 150 ml of
fresh complete DMEM was added to each well 2 h PI. 48 h PI, the
media was removed and 100 ml of ﬁxing solution (1% formaldehyde
in 1XPBS) were added to each well for 5 min. The cells were then
washed twice with 100 ml 1XPBS. This was followed by adding to
each well 50 ml of the staining solution (4 mM potassium ferrocya-
nide, 4 mM potassium ferricyanide, 2 mM MgCl2, and 0.4 mg/ml
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside [X-gal]) and the
plate was incubated for 1 h at 37 1C in a non-CO2 incubator. The
staining was stopped by removing the staining solution and washing
thoroughly twice with 100 ml 1XPBS. Positive infections (shown as
blue cells) were counted under light microscopy in at least three
wells per each virus infection. The resulted numbers of positive cells
were normalized according to equal U5 RTN products.
Molecular cloning
The cloning of the desired single mutant variants of HIV-2 RT
(in pROD10) was performed by overlapping PCR technique in
which the mutation was introduced by two perfectly overlapping
oligos harboring the desired mutation (Cameron et al., 1997). All
PCR-ampliﬁed segments were sequenced to conﬁrm that only the
desired mutation was inserted.
Gene ampliﬁcations and sequencing
In order to compare mutation rates in all studied viruses, inte-
grated viral genome were isolated and ampliﬁed by the two-step Alu-
LTR PCR method (Agosto et al., 2007). Then the ampliﬁed fragments
were cloned by the CloneJet system (Thermo), transformed to DH5α
and the resulted plasmids were sequenced. The obtained sequences
were compared with the sequence of the original plasmid sequence.
Dot blot assay for viral RT-associated RDDP activity
10 ml of virus-containing supernatants were mixed with 40 ml of
reaction buffer (30 mM Tris–HCl, pH 7.5, 5 mM MgCl2, 50 mM KCl,
4 mM DTT, 5U poly(rA)n  oligo(dT)12–18, 6.25 mM dTTP and 0.05 ml
of [α-32P] dTTP, 10 mCi/ml). This was followed by 1 h incubation at
37 1C. Then, 5 ml aliquots were spotted on a DEAE cellulose paper
(Whatman, DE-81), and dried for 5 min at room temperature. The
paper was then washed 3 times with 2XSCC buffer (0.3 M NaCl and
30 mM sodium citrate) and once with 95% ethanol. Then, the dried
paper was exposed to an X-ray ﬁlm (Telesnitsky et al., 1995).
Quantitative PCR (qPCR)
All primers were tested for linearity by standard curve analysis
(in the range of 0.002pg-0.2ng). Those primers were primers used
for HIV-2 detection (MacNeil et al., 2007), for detecting the control
cellular gene, glyceraldehyde 3-phosphate dehydrogenase (Uni-
versal ProbeLibrary Technology, Rosch. Set #60). The primers, used
for detecting the residual viral original plasmids after infection
(matching plasmid “backbone” sequences), were designed using
the Probe ﬁnder software, Roche. All primers are listed in Table 1.
Each assay was done in triplicates and three independent biolo-
gical experiments were performed.
Bioinformatic analysis
The sequences of SIV and HIV strains used to determine residue
294 conservation were obtained from NCBI (www.ncbi.nlm.nih.
gov), then, aligned and analyzed with the BioEdit program (Hall,
1999). Viral sequences not containing the RT residue 294 region
were omitted from the calculations.
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